

# Infectious Disease Risk Associated with Contaminated Propofol Anesthesia, 1989–2014<sup>1</sup>

Andrés Zorrilla-Vaca, Jimmy J. Arevalo, Kevin Escandón-Vargas, Daniel Soltanifar, Marek A. Mirski

## Medscape **EDUCATION** ACTIVITY

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 **AMA PRA Category 1 Credit(s)**<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/eid>; (4) view/print certificate.

**Release date: May 11, 2016; Expiration date: May 11, 2017**

### Learning Objectives

Upon completion of this activity, participants will be able to:

- Assess the epidemiology of propofol-related infection.
- Identify the procedure associated with the highest number of propofol-related infections.
- Assess different sources of propofol-related infection.
- Evaluate other contributing factors in propofol-related infections.

### CME Editor

**Jean Michaels Jones**, Technical Writer/Editor, *Emerging Infectious Diseases*. *Disclosure: Jean Michaels Jones has disclosed no relevant financial relationships.*

### CME Author

**Charles P. Vega, MD**, Clinical Professor of Family Medicine, University of California, Irvine. *Disclosure: Charles P. Vega, MD, has disclosed the following financial relationships: served as an advisor or consultant for Allergan, Inc.; McNeil Consumer Healthcare; served as a speaker or a member of a speakers bureau for Shire Pharmaceuticals.*

### Authors

*Disclosure: Andrés Zorrilla-Vaca; Jimmy J. Arevalo, MD, MSc; Kevin Escandón-Vargas, MD; Daniel Soltanifar, MBBS, FRCA; and Marek A. Mirski, MD, PhD, have disclosed no relevant financial relationships.*

Author affiliations: Universidad del Valle School of Medicine, Cali, Colombia (A. Zorrilla-Vaca, K. Escandón-Vargas); Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia (J.J. Arevalo); Royal Free Hospital, London, United Kingdom (D. Soltanifar), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (M.A. Mirski)

Administration of propofol, the most frequently used intravenous anesthetic worldwide, has been associated with several iatrogenic infections despite its relative safety. Little is known regarding the global epidemiology of propofol-related outbreaks and the effectiveness of existing preventive strategies. In this overview of the evidence of propofol as a source of

DOI: <http://dx.doi.org/10.3201/eid2206.150376>

<sup>1</sup>Part of this work was presented at the XXXI Colombian Congress of Anesthesiology and Critical Care, Cali, Colombia, July 2015.